This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arscott, P. L. Articles by Baker, J. R. Search for Related Content PubMed PubMed Citation Articles by Arscott, P. L. Articles by Baker, J. R., Jr.

Fas (CD95) Expression is Up-Regulated on Papillary Thyroid Carcinoma¹

Departments of Internal Medicine (P.L.A., T.S., A.M., J.R.B.), Pathology (T.J.G.), and Surgery (N.W.T), University of Michigan, Ann Arbor, Michigan 48109

Address correspondence and requests for reprints to: James R. Baker, Jr., M.D., University of Michigan Medical Center, 1150 West Medical Center Drive, Room 9220 MSRB III, Ann Arbor, Michigan 48109-0648. E-mail: jbakerjr{at}umich.edu

Thyrocyte apoptosis signaled through the Fas receptor has been proposed as a mechanism for the cytotoxicity observed in thyroiditis, but the role the Fas pathway plays in thyroid cancer is not known. We examined Fas expression in thyroid tissue derived from patients with papillary carcinoma and follicular cancer. More intense immunohistological staining for the Fas protein was observed on papillary cancer cells as compared with adjacent normal follicles. To further characterize the expression of Fas in papillary cancer, paired normal and cancerous thyroid tissues were obtained at thyroidectomy from several donors, digested, and placed into cell culture. Messenger RNA was analyzed by ribonuclease protection assays, and protein was identified by flow cytometry. Fas expression was detected at levels up to 3-fold higher in cancerous thyrocytes compared with paired normal cells. To determine whether the expressed Fas antigen was functional, thyrocytes were treated with a monoclonal IgM anti-Fas antibody (clone CH11; Upstate Biotechnology, Inc., Lake Placid, NY) in the presence of interferon- and cycloheximide. Whereas both normal and cancerous thyrocytes were induced to die after this treatment, the cancerous thyrocytes were more sensitive to anti-Fas antibody. This work demonstrates that the Fas antigen is expressed and functional on papillary thyroid cancer cells and this may have potential therapeutic significance.

This article has been cited by other articles:

				R. Mathew and E. White FLIPping the Balance between Apoptosis and Proliferation in Thyroid Cancer. Clin. Cancer Res., June 15, 2006; 12(12): 3648 - 3651. [Full Text] [PDF]

				C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF]

				M. Todaro, M. Zerilli, L. Ricci-Vitiani, M. Bini, M. Perez Alea, A. Maria Florena, L. Miceli, G. Condorelli, S. Bonventre, G. Di Gesu, et al. Autocrine Production of Interleukin-4 and Interleukin-10 Is Required for Survival and Growth of Thyroid Cancer Cells Cancer Res., February 1, 2006; 66(3): 1491 - 1499. [Abstract] [Full Text] [PDF]

				P. Kossmehl, M. Shakibaei, A. Cogoli, M. Infanger, F. Curcio, J. Schonberger, C. Eilles, J. Bauer, H. Pickenhahn, G. Schulze-Tanzil, et al. Weightlessness Induced Apoptosis in Normal Thyroid Cells and Papillary Thyroid Carcinoma Cells via Extrinsic and Intrinsic Pathways Endocrinology, September 1, 2003; 144(9): 4172 - 4179. [Abstract] [Full Text] [PDF]